Acid Reflux or Gastro-Oesophageal Reflux (GOR) is a condition suffered by many individuals at some point in their lives, with some estimates suggesting 60-70% of the population suffering from reflux in any 12-month period. A more severe and chronic progression is diagnosed as Gastro-Oesophageal Reflux Disease (GORD; also known as GERD) approximately 60,000 people are hospitalised with severe GORD a year in Australia alone.
The diagnosis of GORD is generally set by its cardinal symptoms of heartburn and acid regurgitation, occurring at least weekly. The prevalence of these weekly symptomatic events among adults has been reported to be in the range of 10-20% in the western world, with higher prevalence in recent years. A study ranging over the last 10 years including 80,000 subjects revealed an increase of 47% on weekly events with gender and age being significant factors.
- KFSU holds and is presently at the national application phase of a patent for the treatment of acid reflux and gastro-oesophageal reflux disease in the EU, Japan and Australia and has been granted a full patent in the US after final examination.
- The prebiotic phytonutrient fibre extract from sugarcane has an anecdotal record of amelioration of symptoms for both chronic and acute acid reflux/indigestion.
- A lifestyle study recording beneficial effects and a human clinical trial study are currently underway to demonstrate the high efficacy of Kfibre for providing relief of reflux symptoms. Patented treatment formats cover both functional foods and pharmaceutical approaches.
Patent Application “Dietary Supplement for the treatment of acid reflux and gastro-oesophageal reflux disease (GORD/GERD)”
According to an aspect of the invention, there is provided a method of treatment of the chronic and acute effects of Acid reflux or GORD/GERD over an extended period in an individual by feeding to said individual a food product incorporating dietary fibre material extracted from sugar cane.
Clinical Trials – Planning phase for therapeutic evidence
In order to test an alternative GORD/GERD treatment, a clinical trial is currently being conducted using Kfibre compared to a placebo of insoluble crystalline cellulose fibre. The study is being conducted in Launceston by doctors in association with gastric clinics. Results expected Dec 2018.
If you’re a health professional and would like more information or a discussion on the above, please contact us.